Back to search
FDAFDA · Food and drugs·Recall number D-1392-2019

Myorisan (isotretinoin capsules, USP), 40 mg, packaged in cartons of 30 Capsules containing 3 x 10 Prescription Packs, Rx Only, Distributed by: VersaPharm Inc. - An Akorn Company, Lake Forest, IL 60045, NDC 61748-304-13

Published June 26, 2019 · Recall initiated: June 7, 2019

Summary

FDA records drug Class III recall D-1392-2019, published June 26, 2019 and initiated June 7, 2019. Recalling firm: Akorn Inc; Status: Terminated; Reported quantity: 16,216 cartons; Lot: Lot#: V30M56A, Exp 9/20. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is label correctly.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Akorn Inc
Distributor
Nationwide USA
Lot
Lot#: V30M56A, Exp 9/20
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Myorisan (isotretinoin capsules, USP), 40 mg, packaged in cartons of 30 Capsules containing 3 x 10 Prescription Packs, Rx Only, Distributed by: VersaPharm Inc. - An Akorn Company, Lake Forest, IL 60045, NDC 61748-304-13 recalled?

Yes. FDA published recall D-1392-2019 on June 26, 2019. Reported hazard: Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is label correctly.

What should I do if I have this product?

Voluntary: Firm initiated · Letter